Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile
- 8 August 2001
- journal article
- research article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 425 (3), 197-201
- https://doi.org/10.1016/s0014-2999(01)01188-8
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Binding of antipsychotic drugs to human brain receptorsLife Sciences, 2000
- 5-HT1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortexBiological Psychiatry, 2000
- Antipsychotic-Induced Weight Gain: A Comprehensive Research SynthesisAmerican Journal of Psychiatry, 1999
- Comparison of the Novel Antipsychotic Ziprasidone with Clozapine and Olanzapine Inhibition of Dorsal Raphe Cell Firing and the Role of 5-HT1A Receptor ActivationNeuropsychopharmacology, 1999
- Ziprasidone 80 mg/day and 160 mg/day in the Acute Exacerbation of Schizophrenia and Schizoaffective Disorder A 6-Week Placebo-Controlled TrialNeuropsychopharmacology, 1999
- Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [
S ]GTPγS binding studyEuropean Journal of Pharmacology, 1998 - Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsyJournal of Neural Transmission, 1991
- Typical and atypical antipsychotic occupancy of D2 and S2 receptors: An autoradiographic analysis in rat brainBrain Research Bulletin, 1986
- Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic DrugsScience, 1976